Does Benzene Cause Acute Myeloid Leukemia?

From Environmental Health to Occupational Hazard

The Immunodeficiency Foundation has long served as a repository for general health and scientific knowledge, chronicling the broad interplay between environmental factors and human well-being. Its archives document foundational understandings of how external agents can disrupt normal physiological processes, offering a historical lens on public health concerns. Within this legacy, the transition from general environmental health to specific occupational hazards emerges naturally. As industrial chemistry expanded throughout the twentieth century, workplace exposures became a focal point for understanding how concentrated contact with certain substances might influence disease patterns. This shift in perspective moves from population-level observations to more targeted inquiries into particular chemical agents and their potential long-term effects. The case of benzene exemplifies this evolution: once considered merely a common industrial solvent, its association with hematological conditions gradually drew attention from occupational health researchers. The question of whether benzene exposure can lead to acute myeloid leukemia represents a critical intersection of general toxicological principles and workplace safety. This inquiry builds upon the foundation of environmental health science while narrowing focus to the specific risks faced by workers in industries where benzene is prevalent.

Benzene as a Recognized Myelotoxin

Benzene is a well-established myelotoxin and a recognized risk factor for the development of acute myeloid leukemia (AML). Chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms, and it is able to augment the risk for the onset of acute myeloid leukemia, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The causal relationship between occupational benzene exposure and AML has been established in previous studies (https://pubmed.ncbi.nlm.nih.gov/38727681/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). In a national cohort from Switzerland, occupational exposure to benzene was found to be associated with elevated mortality risks for AML (https://pubmed.ncbi.nlm.nih.gov/38727681/). Additionally, meta-analyses have indicated increased risks of childhood AML associated with benzene exposure, with an odds ratio of 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).

Clinical Presentation and Diagnosis of Benzene-Induced AML

The clinical presentation of AML typically includes symptoms related to bone marrow failure, such as fatigue, pallor, fever, infections, and easy bruising or bleeding. Diagnosis is confirmed by peripheral blood smear and bone marrow biopsy showing at least 20% blasts of myeloid lineage. Benzene-induced AML often follows a similar clinical course, but may be preceded by myelodysplastic syndromes (MDS), which are also linked to benzene exposure (https://pubmed.ncbi.nlm.nih.gov/34069279/). The mode of action for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Mechanistic Pathways Linking Benzene to AML

Mechanistic pathways linking benzene to AML involve several biological processes. Possible mechanisms of benzene initiation of hematological tumors have been identified, including a genotoxic effect, an action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). Benzene is metabolized in the liver to reactive intermediates, such as benzene oxide, phenol, and hydroquinone, which can form DNA adducts and cause chromosomal aberrations in hematopoietic stem cells. These genotoxic events can lead to mutations in genes critical for myeloid differentiation and proliferation, such as RUNX1, CEBPA, and NPM1, which are commonly altered in AML. Epigenetic effects, including altered gene expression, are also increasingly recognized as contributing factors, as genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). The key event-informed risk models for benzene-induced AML incorporate these early hematotoxic and genotoxic changes to predict the apical adverse outcomes of morbidity and mortality (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Risk Assessment and Prevention

Regarding risk anchors, the adequacy of warnings about benzene and AML is a critical consideration. Given the established causal relationship, regulatory agencies and occupational safety organizations have set permissible exposure limits for benzene, such as the Occupational Safety and Health Administration (OSHA) permissible exposure limit of 1 ppm over an 8-hour workday. However, warnings may not always be sufficient for all populations, particularly in settings where exposure is intermittent or below regulatory limits but still associated with increased risk. For affected patients, causation-related considerations include the dose, duration, and latency of exposure. The timeline between exposure and documented harm can vary, but occupational studies have shown that chronic exposure over years to decades can lead to AML, with latency periods often ranging from 5 to 20 years. Prevention of early key events, such as hematotoxicity and genetic toxicity, would lead to prevention of the apical adverse outcomes, including morbidity and mortality caused by MDS and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). In summary, the evidence supports a causal link between benzene exposure and AML, with multiple mechanistic pathways involving genotoxicity, oxidative stress, inflammation, and immunosuppression. The risk is particularly elevated at occupational exposure levels of 10 ppm or more, but lower levels may also contribute to increased risk, as seen in childhood AML studies. Adequate warnings and exposure controls are essential to prevent the development of this often-fatal hematologic malignancy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the evidence that benzene causes acute myeloid leukemia?

Multiple studies have established a causal relationship between occupational benzene exposure and AML. Chronic exposure to benzene is a recognized risk factor for AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). Occupational exposure at levels of 10 ppm or more is associated with increased AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/), and meta-analyses show increased childhood AML risk with benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).

What are the mechanisms by which benzene induces leukemia?

Benzene is metabolized to reactive intermediates that form DNA adducts and cause chromosomal aberrations in hematopoietic stem cells. This leads to mutations in genes like RUNX1, CEBPA, and NPM1. Additional mechanisms include oxidative stress, inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). Epigenetic effects also play a role.

What is the typical latency period between benzene exposure and AML diagnosis?

Occupational studies show that chronic exposure over years to decades can lead to AML, with latency periods often ranging from 5 to 20 years. The timeline depends on dose, duration, and individual susceptibility.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.